ADHD medication supply updates and prescribing guidance

As of April 2026, the nationwide shortage of ADHD stimulant medications persists, with recent reports indicating that nearly all major stimulants, including Adderall, Vyvanse, and Concerta, are in critically low supply. The crisis is driven by a combination of sustained high demand, manufacturing capacity limitations, and global supply chain disruptions, rather than solely by DEA production quotas. While pandemic-era telehealth prescribing flexibilities for controlled substances have been extended through December 31, 2026, patients continue to face significant challenges with medication access, often requiring "forced switching" between different molecules or dosage forms.

• Telehealth Flexibility Extension: Pandemic-era telehealth flexibilities for prescribing controlled substances, including ADHD stimulants, are extended through December 31, 2026. 📅 Calendar file (.ics) Expiration of ADHD Telehealth Prescribing Flexibilities December 31, 2026